{'52WeekChange': 0.20837486,
 'SandP52WeekChange': 0.0644362,
 'address1': '675 Massachusetts Avenue',
 'address2': '14th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.3,
 'askSize': 800,
 'averageDailyVolume10Day': 112275,
 'averageVolume': 197776,
 'averageVolume10days': 112275,
 'beta': 1.969334,
 'beta3Year': None,
 'bid': 11.85,
 'bidSize': 1300,
 'bookValue': 4.055,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.49,
 'dayLow': 12.03,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.089,
 'enterpriseToRevenue': 13.704,
 'enterpriseValue': 166226896,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 13.1615715,
 'fiftyTwoWeekHigh': 14.483,
 'fiftyTwoWeekLow': 5.25,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14381896,
 'forwardEps': -3.65,
 'forwardPE': -3.3205478,
 'fromCurrency': None,
 'fullTimeEmployees': 57,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.2009,
 'heldPercentInstitutions': 0.54067004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/sperotherapeutics.com',
 'longBusinessSummary': 'Spero Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on identifying, '
                        'developing, and commercializing novel treatments for '
                        'multi-drug resistant (MDR) bacterial infections and '
                        'rare diseases in the United States. Its product '
                        'candidates include tebipenem pivoxil hydrobromide '
                        '(HBr), an oral carbapenem-class antibiotic to treat '
                        'MDR gram-negative infections for adults; SPR206, a '
                        'direct acting IV-administered agent to treat MDR '
                        'Gram-negative infections in the hospital; and SPR720, '
                        'an oral antibiotic for the treatment of pulmonary '
                        'non-tuberculous mycobacterial disease. Spero '
                        'Therapeutics, Inc. has license agreement with Meiji '
                        'Seika Pharma Co., Ltd. to support the development of '
                        'tebipenem HBr; collaboration agreement with Everest '
                        'Medicines to develop, manufacture, and commercialize '
                        'SPR206 in Greater China, South Korea, and Southeast '
                        'Asian countries; collaboration agreement with Bill & '
                        'Melinda Gates Medical Research Institute to develop '
                        'SPR720 for the treatment of lung infections caused by '
                        'Mycobacterium tuberculosis; and license agreement '
                        'with Vertex Pharmaceuticals Incorporated for patents '
                        'relating to SPR720, as well as SPR719, an active '
                        'metabolite. The company was founded in 2013 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Spero Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 249615040,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_240573619',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -79660000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.45,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.08,
 'phone': '857 242 1600',
 'previousClose': 12.38,
 'priceHint': 2,
 'priceToBook': 2.9889026,
 'priceToSalesTrailing12Months': 20.578321,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.49,
 'regularMarketDayLow': 12.03,
 'regularMarketOpen': 12.45,
 'regularMarketPreviousClose': 12.38,
 'regularMarketPrice': 12.45,
 'regularMarketVolume': 85541,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 20595300,
 'sharesPercentSharesOut': 0.0421,
 'sharesShort': 866860,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 577344,
 'shortName': 'Spero Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0529,
 'shortRatio': 4.18,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SPRO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.25,
 'twoHundredDayAverage': 10.426978,
 'volume': 85541,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://sperotherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}